LABELS · ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

ENOBY

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-01-16
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Enoby in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Enoby in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD- MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Enoby in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Enoby in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Enoby is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Enoby is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Enoby is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Enoby is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Enoby is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Enoby is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

Full extracted label fields

application numbers

BLA761439

boxed warning exact

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Enoby in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Enoby in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD- MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Enoby in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Enoby in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )

brand names

ENOBY

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=815d3ba4-27a1-4a06-925a-a87f35442bdb

generic names

DENOSUMAB-QBDE

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

indications and usage exact

1 INDICATIONS AND USAGE Enoby is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Enoby is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Enoby is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Enoby is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Enoby is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Enoby is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Hikma Pharmaceuticals USA Inc.

matched search terms

cancer

package ndcs

0143-9165-01

product ndcs

0143-9165

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2725566
2725573

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

BLA761439

brand names

ENOBY

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 365
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Enoby is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 0

current approval status

not_reconciled

duplicate text group

dup-dd3c1635345d493a397a

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-8a123365306853fc650a

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 74
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 30

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 165
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Enoby is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 )
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

BLA761439

brand names

ENOBY

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 446
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Enoby is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastat
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 0

current approval status

not_reconciled

duplicate text group

dup-58e128f62af95f29998b

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-1cb2491c8b956700ec7b

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 74
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 30

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 246
end exclusive: true
exact text: to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 )
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 166

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · unclassified context

application numbers

BLA761439

brand names

ENOBY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 536
end exclusive: true
exact text: (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiv
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 47

current approval status

not_reconciled

duplicate text group

dup-b208afa1f3601caa648e

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-49a4d49d910f9afc7515

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 336
end exclusive: true
exact text: of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 )
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 247

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761439

brand names

ENOBY

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 672
end exclusive: true
exact text: gh risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 137

current approval status

not_reconciled

duplicate text group

dup-4fbc5286a4b0d5dee6b7

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-c5768b085a303ebade8a

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 74
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 30

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 472
end exclusive: true
exact text: to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 )
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 337

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · positive indication candidate

application numbers

BLA761439

brand names

ENOBY

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 802
end exclusive: true
exact text: osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Enoby is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 273

current approval status

not_reconciled

duplicate text group

dup-466ef76d98a7841acde4

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-7093fe484cb81508ed26

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 74
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 30

qualifier mentions

context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
583
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start
540

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 602
end exclusive: true
exact text: to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 473

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 6 · positive indication candidate

application numbers

BLA761439

brand names

ENOBY

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1163
end exclusive: true
exact text: ndrogen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Enoby is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men wi
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 403

current approval status

not_reconciled

duplicate text group

dup-5feb0abc5e985ef56eec

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-f4753214a385348b610f

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 703
end exclusive: true
exact text: is indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 691

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 963
end exclusive: true
exact text: 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Enoby is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 603

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA761439

brand names

ENOBY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1317
end exclusive: true
exact text: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Enoby is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteopo
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 764

current approval status

not_reconciled

duplicate text group

dup-e041e44b398425184471

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-3bc9360eb1c9ed5093d0

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1117
end exclusive: true
exact text: In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] .
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 964

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761439

brand names

ENOBY

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1690
end exclusive: true
exact text: rant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Enoby is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Enoby is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 918

current approval status

not_reconciled

duplicate text group

dup-5dfa87e3131d5a93f884

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-dfca92d84f88ae1df02e

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 1197
end exclusive: true
exact text: is indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 1185

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1490
end exclusive: true
exact text: 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Enoby is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] .
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 1118

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA761439

brand names

ENOBY

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2055
end exclusive: true
exact text: ed as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Enoby is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 1291

current approval status

not_reconciled

duplicate text group

dup-1341dcbb31f7d8df406c

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-f8a2963b493231b80ce7

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 1562
end exclusive: true
exact text: is indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 1550

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1855
end exclusive: true
exact text: 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Enoby is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 1491

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · risk or warning

application numbers

BLA761439

brand names

ENOBY

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2282
end exclusive: true
exact text: cture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Enoby is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androge
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 1656

current approval status

not_reconciled

duplicate text group

dup-9ef7bca8627ac721862b

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-25e3a91c6a79e32dba0b

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2082
end exclusive: true
exact text: High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] .
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 1856

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA761439

brand names

ENOBY

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2544
end exclusive: true
exact text: fined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Enoby is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for B
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 1883

current approval status

not_reconciled

duplicate text group

dup-8aaf28fd6319dd3baef7

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-fb60cfcfe80882f71bb5

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 2194
end exclusive: true
exact text: is indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 2182

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2344
end exclusive: true
exact text: 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Enoby is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 2083

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · unclassified context

application numbers

BLA761439

brand names

ENOBY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2655
end exclusive: true
exact text: on Therapy for Prostate Cancer Enoby is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Enoby is indicated as a treatment to increase bone mass in women at high risk for fracture receivi
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 2145

current approval status

not_reconciled

duplicate text group

dup-1c203f03d19cc56f52e2

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-9175b95bb8634181a16d

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2455
end exclusive: true
exact text: In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] .
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 2345

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761439

brand names

ENOBY

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2745
end exclusive: true
exact text: fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Enoby is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 2256

current approval status

not_reconciled

duplicate text group

dup-4cbe2fbf737462e71d41

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-QBDE

ind-span-530468584826e6394597

label id

ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb

positive predicate support span

end: 2575
end exclusive: true
exact text: is indicated
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 2563

qualifier mentions

context exact
1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Enoby is indicated as a treatment to increase bo
kind
stage_or_setting
polarity
not_inferred
span
end
2545
end exclusive
true
exact text
Adjuvant Aromatase Inhibitor Therapy for Br
label id
ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start
2502
context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
2701
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start
2658

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2745
end exclusive: true
exact text: 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Enoby is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 4f345810d08fb4bc6b925691798154a43c16ac6a41b83dece7d53280e433e172
start: 2456

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ddf6eb2a-4e1f-4cb4-992a-c93cbb5c0cfb%22

spl effective date

2026-01-16

spl set id

815d3ba4-27a1-4a06-925a-a87f35442bdb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Preserved source evidence · Not medical advice